Table 2 |
||||
|
Univariate and multivariable regression analyses |
||||
|
Patient characteristics N = 93 |
Risk ratio for detectable HIV-RNA at delivery (95% confidence interval); p-value |
|||
|
|
||||
|
Patients with undetectable HIV-RNA at delivery N = 68 |
Patients with detectable HIV-RNA at delivery N = 25 |
Univariate analyses |
Multivariable regression analyses using generalized linear models |
|
|
|
||||
|
Nationality (N, %) |
||||
|
Italian |
32/39 (82.1%) |
7/39 (17.9%) |
Ref. |
Excluded due to collinearity with cART |
|
Non-Italian |
36/54 (66.7%) |
18/54 (33.3%) |
1.86 (0.86- 4.01); p = 0.099 |
|
|
|
||||
|
Age (mean years, SD) |
31.5 (5.5) |
30.5 (4.99) |
For each year 0.98 (0.93-1.04); p = 0.5 |
For each year 0.99 (0.94-1.05); p = 0.9 |
|
|
||||
|
Calendar year at pregnancy (mean, SD) |
2005.8 (1.6) |
2005.6 (1.3) |
For each year 0.93 (0.76-1.15); p = 0.7 |
For each year 0.96 (0.85-1.10); p = 0.6 |
|
|
||||
|
cART at HIV RNA test (N, %) |
||||
|
0 drugs |
1/9 (11%) |
8/9 (89%) |
4.4 (2.7-7.1); p < 0.0001 |
Dichotomy variable (no cART - versus- any cART) |
|
2 drugs |
6/6 (100%) |
0/6 (0%) |
||
|
≥3 drugs |
61/78 (78%) |
17/78 (22%) |
Ref. 2 or ≥3 drugs (no differences among the 2) |
4.4 (2.7-7.2) P < 0.0001 |
|
|
||||
|
cART relative to pregnancy (N, %) |
||||
|
before 2nd trimester |
49/60 (82%) |
11/60 (18%) |
Ref. any periods (no differences among the 3) |
|
|
2nd trimester |
14/19 (74%) |
5/19 (26%) |
||
|
3rd trimester |
4/5 (80%) |
1/5 (20%) |
||
|
No therapy |
1/9 (11%) |
8/9 (89%) |
4.4 (2.7-7.1); P < 0.0001 |
|
|
|
||||
|
CD4+/mm3 at pregnancy (mean, SD) |
468 (223) |
376 (204) |
For each 50 CD4+/mm3 0.91 (0.84-0.99); P = 0.037 |
For each 50 CD4+/mm3 0.94 (0.89-0.99); P = 0.032 |
|
|
||||
|
Analyses were on patients with plasma viral load measured at the time of delivery (within 30 days before delivery). cART: combination antiretroviral therapy; Ref.: reference category. |
||||
|
Izzo et al. BMC Public Health 2011 11:124 doi:10.1186/1471-2458-11-124 |
||||
